Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACTIVECARE, INC.ACAR · Entity 171054 | Director · Chief Executive Officer | December 11, 2017 | December 19, 2017 |
| Decoy Therapeutics Inc.DCOY · Entity 937 | Chief Financial Officer | August 31, 2026 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACTIVECARE, INC.
Report date December 11, 2017 · Filed December 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Warrants to purchase common stock.SEC Table II · derivative / convertible security · Expires 2022-12-11 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2017-12-11 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Mr. Rosenblum became a director of ActiveCare, Inc. (the "Company") on December 11, 2017. F2: Pursuant to entering into a certain Securities Purchase Agreement dated December 11, 2017 (the "SPA") with the Company, Mr. Rosenblum was issued a promissory note (the "Note") by the Company for a principal sum of $52,631.58 due and payable within six months from issuance. In connection with entering into the SPA and purchase of the Note, the Company issued Mr. Rosenblum a warrant (the "Warrant") to purchase common stock exercisable within five years of the Initial Exercise Date (as defined in the Warrant) as subject to adjustment, with an exercise price per share of Common Stock which shall be the lesser of (i) 80% of the per share price of common stock in the Private Placement (as defined therein), (ii) $3.00 per share, (iii) 80% of the unit, price offering price in the Private Placement (if applicable), or (iv) 80% of the exercise price of any warrants issued in the Private Placement, in each case subject to adjustment hereunder. F3: The aggregate exercise price of the Warrant is $50,000. If the Company fails to repay the balance due under the Note on its maturity Mr. Rosenblum has the right, to convert all or part of the outstanding and unpaid principal sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Common Stock of the Company pursuant to the following conversion formula: number of shares receivable upon conversion equals the dollar amount being converted divided by the Conversion Price. The Conversion Price is the lesser of $3.00 (subject to adjustment for stock splits) or 60% of the lowest trade price in the 25 trading days. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Rosenblum became a director of ActiveCare, Inc. (the "Company") on December 11, 2017.
F2: Pursuant to entering into a certain Securities Purchase Agreement dated December 11, 2017 (the "SPA") with the Company, Mr. Rosenblum was issued a promissory note (the "Note") by the Company for a principal sum of $52,631.58 due and payable within six months from issuance. In connection with entering into the SPA and purchase of the Note, the Company issued Mr. Rosenblum a warrant (the "Warrant") to purchase common stock exercisable within five years of the Initial Exercise Date (as defined in the Warrant) as subject to adjustment, with an exercise price per share of Common Stock which shall be the lesser of (i) 80% of the per share price of common stock in the Private Placement (as defined therein), (ii) $3.00 per share, (iii) 80% of the unit, price offering price in the Private Placement (if applicable), or (iv) 80% of the exercise price of any warrants issued in the Private Placement, in each case subject to adjustment hereunder.
F3: The aggregate exercise price of the Warrant is $50,000. If the Company fails to repay the balance due under the Note on its maturity Mr. Rosenblum has the right, to convert all or part of the outstanding and unpaid principal sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Common Stock of the Company pursuant to the following conversion formula: number of shares receivable upon conversion equals the dollar amount being converted divided by the Conversion Price. The Conversion Price is the lesser of $3.00 (subject to adjustment for stock splits) or 60% of the lowest trade price in the 25 trading days.
Decoy Therapeutics Inc.
Report date August 31, 2026 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,363 |
Reported balance
After 2026-08-31 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-31 · Grant · Acquired 9,682 · Balance 11,363 F1: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months. F2: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months.
F2: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 31, 2026 Filed Sep 2, 2026 21:48 UTC | Decoy Therapeutics Inc. DCOY · Entity 937 | GrantCommon Stock | 9,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001329154-26-000003 · ownership.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,363 F1 · kind: Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months. F2 · balance_after: Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock splits effective on August 15, 2025 and March 6, 2026. Read SEC document |
| November 20, 2025 Filed Nov 20, 2025 16:42 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 20,000 | $0.80 | $16,000.00 |
DisclosureSEC source: 0001615219-25-000177 · wk-form4_1763674926.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,177 F1 · balance_after: Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025. F2 · balance_after: Includes 20 shares of unvested restricted stock granted on January 3, 2023. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 16:37 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001615219-24-000015 · wk-form4_1708637819.xml · derivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2034-02-19 F1 · derivative.exercise_date: 25% of the options are vested on February 20, 2025, and 1/36 of the remaining options vest on each monthly anniversary thereafter for 36 months. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:06 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 6,432 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000025 · wf-form4_167649515529108.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,851 F1 · shares: Restricted stock granted under the Salarius Pharmaceuticals, Inc. 2015 Equity Incentive Plan in lieu of cash for performance bonus. The shares of common stock are subject to a six-month holding period pursuant to the terms of the restricted stock agreement Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 17:35 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001615219-23-000004 · wf-form4_167295812977872.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,419 F1 · kind: Restricted stock granted under the Salarius Pharmaceuticals, Inc.2015 Equity Incentive Plan. 25% of the shares of restricted stock will vest on January 2, 2024, and 1/36 of the remaining shares of restricted stock will vest on monthly anniversary thereafter. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 16:33 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 7,314 | $1.73 | $12,682.48 |
DisclosureSEC source: 0001615219-22-000141 · wf-form4_166785680873414.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,633 F1 · kind: These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c). Read SEC document |
| November 03, 2022 Filed Nov 8, 2022 17:40 UTC Amendment | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 7,314 | $1.73 | $12,682.48 |
DisclosureSEC source: 0001615219-22-000143 · wf-form4a_166794723949586.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,245 F1 · kind: These shares were acquired under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c) Read SEC document |
| November 03, 2022 Filed Dec 12, 2022 18:29 UTC Amendment | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 1,488 | $1.73 | $2,580.19 |
DisclosureSEC source: 0001615219-22-000153 · wf-form4a_167088775808803.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,419 F1 · shares: The Reporting Person's previous Form 4 filed on November 7, 2022 and amended on November 8, 2022 incorrectly reported the Reporting Person acquiring 7,314 shares of common stock under the Salarius Pharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as amended, in transactions that were exempt under both Rule 16b-3(d) and Rule Rule 16b-3(c), when it should have been reported as 1,488 shares of common stock. Read SEC document |
| May 31, 2022 Filed May 31, 2022 17:13 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 28,000 | $0.18 | $5,040.00 |
DisclosureSEC source: 0001615219-22-000085 · wf-form4_165403159108429.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,319 Read SEC document |
| May 03, 2022 Filed May 5, 2022 16:03 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 10,000 | $0.19 | $1,863.00 |
DisclosureSEC source: 0001615219-22-000067 · wf-form4_165178098962212.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,319 F1 · kind: The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| March 03, 2022 Filed Mar 9, 2022 16:03 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 76,246 | $0.39 | $29,812.19 |
DisclosureSEC source: 0001615219-22-000019 · wf-form4_164685975971462.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,319 F1 · shares: The Registrant issued these shares to the reporting person as part of his bonus; which shares were issued in lieu of net cash compensation. The shares were issued at the fair market value of the Registrants common stock on the date of grant. Read SEC document |
| January 20, 2022 Filed Jan 21, 2022 16:03 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001615219-22-000004 · wf-form4_164279899941926.xml · derivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-01-19 F1 · derivative.exercise_date: 25% of the options are fully vested on January 19, 2023, and 1/36 of the remaining options vest on each monthly anniversary thereafter. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 14:54 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 7,787 | $0.72 | $5,591.07 |
DisclosureSEC source: 0001615219-21-000095 · wf-form4_163613842601112.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,073 F1 · kind: The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:11 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 9,563 | $0.57 | $5,422.22 |
DisclosureSEC source: 0001615219-21-000042 · wf-form4_162024909680344.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,286 F1 · kind: The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 17:02 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0001615219-20-000120 · wf-form4_160711931578964.xml · derivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-12-01 F1 · derivative.exercise_date: 25% of the options are fully vested on December 1, 2021, and 1/36 of the remaining options vest on each monthly anniversary thereafter. Read SEC document |
| November 03, 2020 Filed Nov 5, 2020 17:42 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock | 4,723 | $0.56 | $2,649.60 |
DisclosureSEC source: 0001615219-20-000104 · wf-form4_160461612138517.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,723 F1 · kind: The reporting person voluntarily agreed to receive a percentage of his base salary in issuer shares and receive these shares in lieu of net cash compensation. Shares are purchased at a price determined pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| August 17, 2020 Filed Aug 18, 2020 08:35 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 5,000 | $1.00 | $5,000.00 |
DisclosureSEC source: 0001615219-20-000092 · wf-form4_159775410165354.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Read SEC document |
| July 14, 2020 Filed Jul 16, 2020 20:55 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantStock Option (right to buy) · Derivative | 49,955 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001615219-20-000080 · wf-form4_159494732561482.xml · derivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,955 Underlying: Common Stock · 49,955 shares Expires 2030-07-13 F1 · derivative.exercise_date: 25% of the options are fully vested on July 14, 2021, and 1/36 of the remaining options vest on each monthly anniversary thereafter. Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 18:03 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | GrantCommon Stock · Derivative | 30,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001615219-20-000027 · wf-form4_158517376702567.xml · derivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-03-22 F1 · derivative.exercise_date: 25% of the options granted are fully vested on March 23, 2021, and quarterly vesting of the remaining options over 3 years Read SEC document |
| February 19, 2020 Filed Feb 20, 2020 16:07 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 2,000 | $0.95 | $1,900.00 |
DisclosureSEC source: 0001615219-20-000005 · wf-form4_158223286008604.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| February 13, 2020 Filed Feb 13, 2020 17:57 UTC | Decoy Therapeutics Inc. SLRX · Entity 937 | PurchaseCommon Stock | 5,000 | $0.86 | $4,295.00 |
DisclosureSEC source: 0001615219-20-000001 · wf-form4_158163463653747.xml · nonDerivative · entry 1 Rosenblum Mark J · CIK 0001329154 · Exec VP Finance, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.